Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$649.35B+106.85%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Naoki Okamura
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 14,099
- Beta
- 0.09
- Country
- JP
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.98
Financials
Revenue
$649.35B+106.9%Net Income
$143.54B+196.3%EBITDA
$238.73B+198.2%Free Cash Flow
$76.00B+20.3%EPS (diluted)
$80.73+254.5%Shares Outstanding (diluted)
1.80B-15.6%Operating Expenses
$300.70BCash & Debt
$243.08BReturn of Capital
$71.39BDividend per Share
$0.26Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $2.27T | $309.12B | $172.56 |
| 2025 | $1.91T | $50.75B | $28.35 |
| 2024 | $1.60T | $17.05B | $9.51 |
| 2023 | $1.52T | $98.71B | $54.24 |
| 2022 | $1.30T | $124.09B | $67.08 |
| 2021 | $1.25T | $120.59B | $64.93 |
| 2020 | $1.30T | $195.41B | $104.15 |
| 2019 | $1.31T | $222.26B | $115.05 |
| 2018 | $1.30T | $164.68B | $81.11 |
| 2017 | $1.31T | $218.70B | $103.69 |
| 2016 | $1.37T | $193.69B | $89.75 |
| 2015 | $1.25T | $135.86B | $61.40 |
| 2014 | $1.14T | $90.87B | $40.39 |
| 2013 | $1.01T | $82.85B | $36.03 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ALPMY's reported EPS growth of 12.8% a year over 13 years.
- EPS in 5 years
- $315.17
- Implied price
- $4,728
- Return from $14.21
- 219.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2,350 — today's price is already 99.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| 2.8% | 173.6% | 182.9% | 191.1% | 198.5% | 205.2% |
| 7.8% | 186.9% | 196.7% | 205.3% | 213.0% | 220.1% |
| 12.8% | 200.2% | 210.4% | 219.5% | 227.6% | 234.9% |
| 17.8% | 213.5% | 224.2% | 233.6% | 242.1% | 249.8% |
| 22.8% | 226.9% | 238.0% | 247.8% | 256.6% | 264.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (2)
- Newszacks.com·34d ago·Negative
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
View source ↗ - Newszacks.com·48d ago·Neutral
New Strong Sell Stocks for August 19th ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.39 per share
Typical surprise +50.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.50 vs $0.34beat
- Mon, Apr 27$0.15 vs $0.19miss
- Wed, Feb 4$0.36 vs $0.29beat
- Thu, Oct 30$0.30 vs $0.20beat
- Wed, Jul 30$0.25 vs $0.14beat
- Fri, Apr 25$0.27 vs $0.15beat
Estimates and results for ALPMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (42d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Apr 7, 2020 (20d later)Buy$15,001 - $50,000
- Greg Gianfortehouse · MT00 · disclosed Dec 11, 2018 (22d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.